This September 24, 2026 HHS OIG data brief examines how CMS’s price-substitution policy, using 2024 average sales prices, affected Medicare Part B drug payments. The brief is directly relevant to drug cost containment because it measures how payment substitutions changed Medicare spending for Part B drugs. It differs from earlier published items by focusing narrowly on the payment impact of a specific Part B pricing policy rather than broader Medicare reforms or beneficiary out-of-pocket costs.
